Elevance Health (ELV) EVP & CFO Mark Kaye Sells $4.7M of Stock
Key Points
- Elevance Health, Inc. EVP & CFO Mark Kaye sold 10,584 shares on October 22, 2026, lowering his stake to 19,919 shares.
- The stock traded around $445.28 recently, sitting above both its 50-day and 200-day moving averages.
- Multiple major financial firms updated their price targets for the healthcare plan provider on October 22, 2026.
Since the trade, $ELV is down 0.8% to date (from the $445.28 close on Oct 22, 2026).
Get Elevance Health text alerts
We text you when insiders, Congress, analysts or big funds move on $ELV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Elevance Health, Inc. alert may contain errors. Disclosures
Elevance Health, Inc. EVP & CFO Mark Kaye sold 10,584 shares of the company on October 22, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The transaction was executed at an average price of $440.13, totaling roughly $4.66 million. Following the sale, the officer holds 19,919 shares, cutting his direct stake by about 34.7%. The trade was not carried out under a pre-arranged Rule 10b5-1 plan.
ELV
Elevance Health, Inc.
Inside Mark Kaye's Elevance Health Trade
The EVP & CFO parted with 10,584 shares in a single transaction on October 22, 2026. The shares were sold at $440.13 each for a total value of $4,658,357.09. This move reduced his direct ownership percentage by 34.7%, leaving him with 19,919 shares of the health benefits provider.
Other Institutional Activity in Elevance Health
Other large funds made notable adjustments to their holdings in the health plan provider recently. Bank of Nova Scotia grew its holdings by 104,212 shares, ending with 237,998 shares worth about $93.55 million. Eagle Capital Management boosted its position by adding 44,559 shares, resulting in a total of 1,548,610 shares valued at roughly $618.17 million. Sanders Capital, LLC reduced its stake by 69,556 shares, closing the period with 5,825,024 shares worth about $2.58 billion. Harris Associates L.P. lifted its holdings by 128,065 shares to reach 4,924,511 shares valued at about $2.18 billion. Artisan Partners Limited Partnership trimmed its position by 546,055 shares, leaving it with 4,581,222 shares worth approximately $2.03 billion.
Elevance Health, Inc. Stock Up 2.6%
The stock closed at $445.28 on October 22, 2026, and recently traded around that same price. Shares sit about 1.2% below their 52-week high of $450.69 while resting comfortably above the 50-day moving average of $407.21 and the 200-day moving average of $370.77.
Recent Earnings
For recent earnings context, the company reported trailing twelve month revenue of $201.11 billion and earnings of $23.55 per share.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
9 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 15.1%. Revenue beat estimates by 3.1%.
-
Profit surprise
EBITDA missed by 25 percent. Operating income missed by 25 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 upgrades, 9 target raises, 1 target cut.
-
Earnings quality
Gross margin down 9.6 points. Operating margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Elevance Health delivered stronger than expected first quarter results with earnings per share of $12.58 beating the $10.68 consensus. Revenue came in at $50.2 billion, above the $48.7 billion expected. The company is executing on cost management initiatives in Medicaid and Medicare, with favorable claims experience and improved performance from AI and care delivery programs through Carelon. Management highlighted strong commercial selling momentum for 2027 with record pipelines and employer focus on affordability.
Guidance Management raised full year adjusted earnings guidance to at least $26.75 per share. They expect 2027 earnings to grow at least 12 percent from a revised 2026 baseline of $25.75. The company is confident in this outlook based on improving cost trend management and better than expected first quarter performance.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Dividend
The company pays an annual dividend rate of $6.88 per share.
Insider Buying and Selling at Elevance Health, Inc.
Earlier insider trades at the firm included sales by director Robert L Dixon Jr and officer Ronald W Penczek, alongside purchases by director Ramiro G Peru and CEO Gail A Koziara Boudreaux.
Analysts Set New Price Targets
UBS maintained a Buy rating and raised its target to $523.00, Guggenheim maintained a Buy rating with a target of $485.00, Morgan Stanley kept an Equal-Weight rating with a $449.00 target, RBC Capital held a Sector Perform rating with a $455.00 target, and Barclays kept an Overweight rating and lifted its target to $472.00.
About Elevance Health
Headquartered in Indianapolis, Indiana, Elevance Health operates as a health benefits company in the United States through four primary segments, serving millions of members and providing various health care services and pharmacy solutions.
Bottom Line
Investors will watch for the company's next earnings report on January 28, 2027, for further financial updates. Insider transactions like this one provide a look at how executive ownership changes over time.
Related Filing Alerts
Source: Mark Kaye's Form 4 filing on $ELV (Oct 22, 2026). Written by software, not financial advice. How we make alerts